New Regulatory Regime For 8 Medical Items Under Drugs And Cosmetics Act

New Delhi : Adopting a proactive and sensitive approach to address the needs of the Indian Industry, the Union Ministry of Health & Family Welfare has taken a significant decision for ensuring continued access of eight regulated medical devices today.

The Ministry had earlier notified the following medical items to be regulated under the Drugs and Cosmetics Act which was to come into effect from 1st April, 2021 (as per S.O. 775(E) dated 08th February, 2019 under Medical Devices Rules 2017):

  1. All Implantable Medical Devices;
  2. CT scan equipment;
  3. MRI equipment;
  4. Defibrillators;
  5. PET Equipment;
  6. Dialysis Machine;
  7. X-Ray Machine; and
  8. Bone marrow cell separator.

Accordingly, as per the said order the importers/manufacturers are required to take import/manufacturing licence from Central Licencing Authority or State Licencing Authority, as the case may be, for import/manufacture of above devices, w.e.f. 1st April, 2021.

In order to ensure  supply chain continuity and access to these Medical Devices, while implementing  smooth transition into the new regulatory regime, Union Ministry of Health and Family Welfare has now decided that in case an existing importer/manufacturer who is already importing /manufacturing any of these devices, has submitted application to Central Licencing Authority or State Licencing Authority, as the case may be, for grant of import /manufacturing licence in respect of the said device(s) under the provisions of MDR, 2017, the said application shall be deemed valid and the importer/manufacturer can continue to import /manufacture the said device(s) up to 6 months from issue of this order or till the time, the Central Licencing Authority or State Licencing Authority, as the case may be, takes a decision on the said application, whichever is earlier. Order in this regard has been issued by Drugs Controller General (India) on 18th April 2021 through CDSCO website.

[pdf-embedder url=”https://medicarepharmabusiness.com/wp-content/uploads/2021/04/MDnotice18-190421073032.pdf”]

  • Related Posts

    Ministry declares PCI’s regulation on pharmacist recruitment, promotion and services as ultra vires

    The ministry of health and family welfare has declared the Pharmacy Council of India’s (PCI) recently notified regulation on the pharmacist recruitment, promotion and services as ultra vires and does…

    Second Documented Case of Pan-Drug Resistant Candida auris Uncovered in Kenya

    NAIROBI/GENEVA— In an alarming development that underscores the accelerating global crisis of antimicrobial resistance, researchers have confirmed the detection of a rare, pan-drug resistant strain of the high-priority fungal pathogen…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Ministry declares PCI’s regulation on pharmacist recruitment, promotion and services as ultra vires

    Ministry declares PCI’s regulation on pharmacist recruitment, promotion and services as ultra vires

    Second Documented Case of Pan-Drug Resistant Candida auris Uncovered in Kenya

    Second Documented Case of Pan-Drug Resistant Candida auris Uncovered in Kenya

    AstraZeneca Pharma India opens new Mumbai corporate office, marking the next phase of growth through innovation

    AstraZeneca Pharma India opens new Mumbai corporate office, marking the next phase of growth through innovation

    Pharmaceuticals export reports around 4.9 per cent growth in H1 FY27

    Pharmaceuticals export reports around 4.9 per cent growth in H1 FY27

    NDLEA Intercepts Massive ₦6.98 Billion Tramadol Shipment Imported from India at Lagos Port

    NDLEA Intercepts Massive ₦6.98 Billion Tramadol Shipment Imported from India at Lagos Port

    Two More Pregnant Women In Rajasthan’s Kota Die From Kidney Complications

    Two More Pregnant Women In Rajasthan’s Kota Die From Kidney Complications